keyword
MENU ▼
Read by QxMD icon Read
search

HAS-BLED SCORE

keyword
https://www.readbyqxmd.com/read/29122636/clinical-outcomes-and-history-of-fall-in-patients-with-atrial-fibrillation-treated-with-oral-anticoagulation-insights-from-the-aristotle-trial
#1
Meena P Rao, Dragos Vinereanu, Daniel M Wojdyla, John H Alexander, Dan Atar, Elaine M Hylek, Michael Hanna, Lars Wallentin, Renato D Lopes, Bernard J Gersh, Christopher B Granger
PURPOSE: We assessed outcomes among anticoagulated patients with atrial fibrillation (AF) and a history of falling, and whether the benefits of apixaban versus warfarin are consistent in this population. METHODS: Of the 18,201 patients in ARISTOTLE, 16,491 had information about history of falling - 753 with history of falling and 15,738 without history of falling. The primary efficacy outcome was stroke or systemic embolism; the primary safety outcome was major bleeding...
November 6, 2017: American Journal of Medicine
https://www.readbyqxmd.com/read/29121723/atrial-fibrillation-and-use-of-antithrombotic-medications-in-older-people-a-population-based-study
#2
Mozhu Ding, Laura Fratiglioni, Kristina Johnell, Johan Fastbom, Maria Ljungdahl, Chengxuan Qiu
BACKGROUND: Trends in the use of antithrombotic drugs in elderly patients with atrial fibrillation (AF) are largely unknown. We estimated the prevalence of AF in an older population, and examined whether use of anticoagulant and antiplatelet drugs in older AF patients has changed over time. METHODS: Data from the population-based Swedish National study on Aging and Care in Kungsholmen (n=3363, age≥60years, 64.9% women) were used (2001-2004 and 2007-2010). AF cases were identified through 12-lead electrocardiogram, physician examinations, and patient register records (ICD-10 code I48)...
December 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/29106523/combining-watchman-left-atrial-appendage-closure-and-catheter-ablation-for-atrial-fibrillation-multicentre-registry-results-of-feasibility-and-safety-during-implant-and-30-days-follow-up
#3
Karen P Phillips, Evgeny Pokushalov, Aleksandr Romanov, Sergey Artemenko, Richard J Folkeringa, Tamas Szili-Torok, Gaetano Senatore, Kenneth M Stein, Omar Razali, Nicole Gordon, Lucas V A Boersma
Aims: Long-term results from catheter ablation therapy for atrial fibrillation (AF) remain uncertain and clinical practice guidelines recommend continuation of long-term oral anticoagulation in patients with a high stroke risk. Left atrial appendage closure (LAAC) with Watchman has emerged as an alternative to long-term anticoagulation for patients accepting of the procedural risks. We report on the initial results of combining catheter ablation procedures for AF and LAAC in a multicentre registry...
July 3, 2017: Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology
https://www.readbyqxmd.com/read/29095971/quality-of-oral-anticoagulation-with-vitamin-k-antagonists-in-real-world-patients-with-atrial-fibrillation-a-report-from-the-prospective-multicentre-fantasiia-registry
#4
María Asunción Esteve-Pastor, José Miguel Rivera-Caravaca, Inmaculada Roldán-Rabadán, Vanessa Roldán, Javier Muñiz, Paula Raña-Míguez, Martín Ruiz-Ortiz, Ángel Cequier, Vicente Bertomeu-Martínez, Lina Badimón, Manuel Anguita, Gregory Y H Lip, Francisco Marín
Aims: The efficacy and safety of oral anticoagulation (OAC) using the vitamin K antagonists (VKA) are closely associated with the quality of anticoagulation, reflected by time in therapeutic range (TTR). The SAMe-TT2R2 is a risk score developed to predict the quality of anticoagulation control among VKA users. To analyse the quality of anticoagulation and its clinical determinants based on different methods in a prospective cohort of atrial fibrillation patients on VKA treatment participating in the multicentre Spanish observational registry FANTASIIA...
October 31, 2017: Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology
https://www.readbyqxmd.com/read/29092916/use-of-oral-anticoagulants-in-combination-with-antiplatelet-s-in-atrial-fibrillation
#5
Caroline Sindet-Pedersen, Laila Staerk, Morten Lamberts, Thomas Alexander Gerds, Jeffrey S Berger, Anders Nissen Bonde, Jannik Langtved Pallisgaard, Morten Lock Hansen, Christian Torp-Pedersen, Gunnar H Gislason, Jonas Bjerring Olesen
OBJECTIVES: To investigate temporal trends in the use of non-vitamin K oral anticoagulants (NOACs) and vitamin K antagonists (VKAs) in combination with aspirin and/or clopidogrel in patients with atrial fibrillation (AF) following acute myocardial infarction (MI) and/or percutaneous coronary intervention (PCI). METHODS: Using Danish nationwide registries, all patients with AF who survived 30 days after discharge from MI and/or PCI between 22 August 2011 and 30 September 2016 were identified...
November 1, 2017: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/29083968/effect-of-apixaban-versus-warfarin-use-on-health-care-resource-utilization-and-costs-among-elderly-patients-with-nonvalvular-atrial-fibrillation
#6
Steven Deitelzweig, Xuemei Luo, Kiran Gupta, Jeffrey Trocio, Jack Mardekian, Tammy Curtice, Melissa Lingohr-Smith, Brandy Menges, Jay Lin
BACKGROUND: The clinical trial ARISTOTLE showed that apixaban was superior to warfarin in reducing the risks of stroke and bleeding among patients with nonvalvular atrial fibrillation (NVAF). Further study of the effect of apixaban versus warfarin use on health care resource utilization (HCRU) and associated costs in the real-world setting is warranted, especially among elderly patients who are at higher risk of stroke and bleeding. OBJECTIVE: To compare HCRU and costs among elderly NVAF patients treated with apixaban versus warfarin in the United States...
November 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29080549/predicted-risk-of-stroke-and-bleeding-and-use-of-oral-anticoagulants-in-atrial-fibrillation-danish-nationwide-temporal-trends-2011-2016
#7
Alexandar Dukanovic, Laila Staerk, Emil Loldrup Fosbøl, Kasper Gadsbøll, Gunnar Hilmar Gislason, Jonas Bjerring Olesen
INTRODUCTION, MATERIALS AND METHODS: We used Danish nationwide registries to examine temporal trends in the predicted stroke and bleeding risks (mean CHA2DS2-VASc and HAS-BLED scores per year, respectively) as well as the combination of selected stroke and bleeding risk factors per year among atrial fibrillation (AF) patients initiated for the first time between 2011 and 2016 on vitamin K antagonists (VKAs), dabigatran, rivaroxaban, or apixaban. RESULTS: In total, 53,860 AF patients were included (VKA 37...
October 16, 2017: Thrombosis Research
https://www.readbyqxmd.com/read/29076078/anticoagulant-therapy-in-atrial-fibrillation-for-stroke-prevention-assessment-of-agreement-between-clinicians-decision-and-cha2ds2-vasc-and-has-bled-scores
#8
Marzieh Balaghi-Inalou, Saeed Alipour Parsa, Latif Gachkar, Sasan Andalib
INTRODUCTION: To prevent stroke, anticoagulants should be administered after calculation of CHA2DS2-VASc and HAS-BLED scores in patients with Atrial Fibrillation (AF); nonetheless, these scores are sometimes neglected in clinical settings. AIM: The present study was designed to assess agreement of anticoagulant therapy according to clinicians and CHA2DS2-VASc and HAS-BLED scores in Iranian AF patients in Moddares Hospital. METHODS: AF patients were diagnosed according to clinical history, clinical examination, and electrocardiogram...
October 26, 2017: High Blood Pressure & Cardiovascular Prevention: the Official Journal of the Italian Society of Hypertension
https://www.readbyqxmd.com/read/29069203/first-results-of-the-brazilian-registry-of-percutaneous-left-atrial-appendage-closure
#9
Ênio Eduardo Guérios, Francisco Chamié, Márcio Montenegro, Eduardo Benchimol Saad, Fabio Sandoli de Brito, Paulo Avancini Caramori, Luiz Carlos Simões, Flávio Roberto Azevedo de Oliveira, Luiz Carlos Giuliano, Cláudio Munhoz da Fontoura Tavares
BACKGROUND: Left atrial appendage closure (LAAC) is an effective alternative to oral anticoagulation (OA) for the prevention of stroke in patients with non-valvular atrial fibrillation (NVAF). OBJECTIVE: To present the immediate results and late outcomes of patients submitted to LAAC and included in the Brazilian Registry of Percutaneous Left Atrial Appendage Closure. METHODS: 91 patients with NVAF, high stroke risk (CHA2DS2VASc score = 4...
October 19, 2017: Arquivos Brasileiros de Cardiologia
https://www.readbyqxmd.com/read/29044861/comparison-of-bleeding-risk-scores-in-patients-with-atrial-fibrillation-insights-from-the-re-ly-trial
#10
M Proietti, Z Hijazi, U Andersson, S J Connolly, J W Eikelboom, M D Ezekowitz, D A Lane, J Oldgren, V Roldan, S Yusuf, L Wallentin
BACKGROUND: Oral anticoagulation is the mainstay of stroke prevention in atrial fibrillation (AF), but must be balanced against the associated bleeding risk. Several risk scores have been proposed for prediction of bleeding events in patients with AF. OBJECTIVES: To compare the performance of contemporary clinical bleeding risk scores in 18 113 patients with AF randomized to dabigatran 110 mg, 150 mg or warfarin in the RE-LY trial. METHODS: HAS-BLED, ORBIT, ATRIA and HEMORR2 HAGES bleeding risk scores were calculated based on clinical information at baseline...
October 16, 2017: Journal of Internal Medicine
https://www.readbyqxmd.com/read/29039622/quality-of-vitamin-k-antagonist-oral-anticoagulation-in-322-patients-with-atrial-fibrillation-real-life-data-from-a-survey-in-eastern-switzerland
#11
Micha Tobias Maeder, Tabea König, Sanja Bogdanovic, Irene Schneider, Werner Eugster, Peter Ammann, Marius König, Jürg Beer, Hans Rickli
AIM OF THE STUDY: To better appreciate the role of the non-vitamin K oral anticoagulants (NOACs) for patients with non-valvular atrial fibrillation in Switzerland we aimed to assess the quality of vitamin K antagonist (VKA) anticoagulation in daily practice. METHODS: In a cross-sectional study, clinically stable patients on VKA treatment for non-valvular atrial fibrillation for at least 6 months, documentation of international normalised ratio (INR) values for at least 3 months and with at least two INR values were included...
October 17, 2017: Swiss Medical Weekly
https://www.readbyqxmd.com/read/29016755/outcomes-after-catheter-ablation-and-cardioversion-in-patients-with-non-valvular-atrial-fibrillation-results-from-the-prospective-observational-xantus-study
#12
A John Camm, Alexander G G Turpie, Susanne Hess, Pierre Amarenco, Marc Lambelet, Sylvia Haas, Martin van Eickels, Paulus Kirchhof
Aims: In patients with atrial fibrillation, catheter ablation and cardioversion carry a risk of peri-procedural thromboembolic events; current guidelines recommend anticoagulation in these settings. This study aimed to report the baseline demographics and clinical characteristics of patients enrolled in the prospective, observational XANTUS study who underwent catheter ablation or cardioversion, and adverse outcomes with each of these procedures in patients treated with rivaroxaban. Methods and results: Data collected included information on catheter ablation and cardioversion, and adverse outcomes occurring within 30 days of these procedures: incidence of treatment-emergent adjudicated symptomatic thromboembolic events and major bleeding; and cardiovascular and all-cause death...
July 7, 2017: Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology
https://www.readbyqxmd.com/read/29016695/oral-anticoagulant-persistence-in-patients-with-non-valvular-atrial-fibrillation-a-cohort-study-using-primary-care-data-in-germany
#13
Shuk-Li Collings, Cinira Lefèvre, Michelle E Johnson, David Evans, Guido Hack, Gillian Stynes, Andrew Maguire
This study examined characteristics and treatment persistence among patients prescribed oral anticoagulants (OACs) for stroke prevention in non-valvular atrial fibrillation (NVAF). We identified 15,244 patients (51.8% male, 72.7% aged ≥70) with NVAF and no prior OAC therapy who were prescribed apixaban (n = 1,303), rivaroxaban (n = 5,742), dabigatran (n = 1,622) or vitamin-K antagonists (VKAs, n = 6,577) between 1-Dec-2012 and 31-Oct-2014 in German primary care (IMS® Disease Analyzer). We compared OAC persistence using Cox regression over patients' entire follow-up and using a data-driven time-partitioned approach (before/after 100 days) to handle non-proportional hazards...
2017: PloS One
https://www.readbyqxmd.com/read/28994871/evaluation-of-anticoagulation-therapy-in-non-valvular-atrial-fibrillation-in-the-emergency-department
#14
Hanen Ghazali, Jihen Essid, Anware Yahmadi, Moez Mougaida, Mahbouba Chkir, Sami Souissi
INTRODUCTION: The vitamin K antagonists (VKAs) are currently the most effective therapeutic class for the prevention of cerebrovascular eventsin atrial fibrillation (AF) patients. However, several studies showed an under-prescription of this therapy.The aim of the study was to assess the prescription of VKAs in non-valvular AF (NVAF) patients and factors influencing the non-prescription ofsuch treatment. METHODS: We conducted a prospective, observational study in an emergency department (ED)...
November 2016: La Tunisie Médicale
https://www.readbyqxmd.com/read/28992980/adherence-to-recommendations-of-the-therapeutic-positioning-report-about-treatment-with-oral-anticoagulants-in-elderly-patients-with-atrial-fibrillation-the-esparta-study
#15
Carmen Suárez Fernández, Jose María Mostaza, Luis Castilla Guerra, Jesus Cantero Hinojosa, Josep Maria Suriñach, Fernando Acosta de Bilbao, Juan José Tamarit, José Luis Diaz Diaz, Jose Luis Hernandez, Daniel Cazorla, Carles Ràfols
BACKGROUND AND OBJECTIVE: To evaluate the adherence to the recommendations in clinical practice performed by the Therapeutic Positioning Report (TPR) of the Spanish Agency of Medicines and Sanitary Products about the treatment with oral anticoagulants in patients aged≥75 years old with nonvalvular atrial fibrillation (NVAF) treated in Internal Medicine departments in Spain. PATIENTS AND METHODS: Observational, cross-sectional and multicenter study in which 837 patients aged≥75 years old with NVAF, with stable treatment with oral anticoagulants at least 3 months before inclusion, and that had started treatment with oral anticoagulants before the inclusion period were included...
October 6, 2017: Medicina Clínica
https://www.readbyqxmd.com/read/28991879/risks-versus-benefits-of-anticoagulation-for-atrial-fibrillation-in-cirrhotic-patients
#16
Jonggi Choi, Junhwan Kim, Ju Hyun Shim, Minsu Kim, Gi-Byoung Nam
BACKGROUND & AIMS: To evaluate the clinical benefits and risks of anticoagulation with warfarin in cirrhotic patients with atrial fibrillation (AF). METHODS: A total of 465 cirrhotic patients diagnosed with nonvalvular AF were retrospectively analyzed. We compared incidences of ischemic stroke and major bleeding events between the 2 groups and examined the factors predicting ischemic stroke or major bleeding events. RESULTS: Of 465 patients with AF, 113 (24...
October 2017: Journal of Cardiovascular Pharmacology
https://www.readbyqxmd.com/read/28990646/-clinical-profile-and-satisfaction-with-anticoagulated-treatment-in-patients-with-non-valvular-atrial-fibrillation-attended-in-internal-medicine-and-neurology-departments-of-spain
#17
(no author information available yet)
AIM: To determine the clinical profile, management of anticoagulant treatment and satisfaction related to anticoagulation in outpatients with nonvalvular atrial fibrillation attended in Neurology or Internal Medicine departments of Spain. PATIENTS AND METHODS: Cross-sectional and multicenter study, in which 1,337 outpatients were included. Patients fulfilled ACTS, SAT-Q and EQ-5D questionnaires. RESULTS: 865 patients (64.7%) were recruited from Neurology department and 472 (35...
October 16, 2017: Revista de Neurologia
https://www.readbyqxmd.com/read/28980285/peri-interventional-combined-anticoagulation-and-antithrombotic-therapy-in-atrial-fibrillation-ablation-a-retrospective-safety-analysis
#18
Katharina Klee, Daniel Widulle, Martin Duckheim, Michael Gramlich, Christian Frische, Meinrad Gawaz, Peter Seizer, Christian Eick, Juergen Schreieck
BACKGROUND: Catheter ablation (CA) of atrial fibrillation (AF) requires an intensified peri-interventional anticoagulation scheme to avoid thromboembolic complications. In patients with cardiac or extracardiac artery disease, an additional antiplatelet treatment (AAT) is at least temporally necessary especially after a percutaneous intervention with stent implantation. This raises the question whether these patients have a higher peri-interventional bleeding risk during CA of AF. METHODS: The data of 1235 patients with CA of AF were retrospectively analyzed in terms of bleeding events, ablation type, antithrombotic medication and comorbidities such as coronary artery disease and components of the HAS- BLED Score...
October 5, 2017: Cardiology Journal
https://www.readbyqxmd.com/read/28969968/efficacy-and-safety-of-rivaroxaban-in-extreme-elderly-patients-with-atrial-fibrillation-analysis-of-the-shikoku-rivaroxaban-registry-trial-srrt
#19
Shigenobu Bando, Akiyoshi Nishikado, Norikazu Hiura, Shuntaro Ikeda, Akiyoshi Kakutani, Katsuhito Yamamoto, Noriyoshi Kaname, Masahiko Fukatani, Yuichiro Takagi, Kazushi Yukiiri, Yamato Fukuda, Yutaka Nakaya
BACKGROUND: The Shikoku Rivaroxaban Registry Trial (SRRT) is a retrospective survey of the use of rivaroxaban for stroke prevention in elderly patients in Shikoku, Japan. METHODS: The SRRT enrolled 1339 patients from 8 hospitals. Patients were divided into two groups according to their age, the extreme elderly group (453 patients aged ≧80 years) and the control group (886 patients aged <80 years). RESULTS: In the extreme elderly group, 41...
September 29, 2017: Journal of Cardiology
https://www.readbyqxmd.com/read/28968197/safety-of-once-or-twice-daily-dosing-of-non-vitamin-k-antagonist-oral-anticoagulants-noacs-in-patients-with-nonvalvular-atrial-fibrillation-a-noac-tr-study
#20
Sadık Volkan Emren, Mehdi Zoghi, Rida Berılgen, İbrahim Halil Özdemir, Oğuzhan Çelik, Nurullah Çetin, Asım Enhoş, Cemal Köseoğlu, Abdurrahman Akyüz, Volkan Doğan, Fatih Levent, Yüksel Dereli, Tolga Doğan, Özcan Başaran, Ilgın Karaca, Özkan Karaca, Yılmaz Ömür Otlu, Çağlar Özmen, Selvi Coşar, Mutlu Sümerkan, Erdal Gürsul, Sinan İnci, Ersel Onrat, Oktay Ergene
Once-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) may increase patient adherence to treatment but may also be associated with a higher risk of bleeding. In this study, we investigated the adherence to once- or twice-daily dosing of NOACs and the risk of bleeding in nonvalvular atrial fibrillation (NVAF) patients. This multicenter cross-sectional study, conducted between 1 September 2015 and 28 February 2016, included 2214 patients receiving NOACs for at least 3 months, due to NVAF. Patients receiving once-daily or twice-daily NOAC doses were 1:1 propensity score matched for baseline demographic characteristics and the presence of other diseases...
October 2, 2017: Bosnian Journal of Basic Medical Sciences
keyword
keyword
29919
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"